Want to see HK:2216 full AI Analyst Report?
2216 Stock Chart & Stats
HK$2.36
HK$0.01(1.61%)
At close: 4:00 PM EST
HK$2.36
HK$0.01(1.61%)
Day’s Range― - ―
52-Week RangeHK$0.53 - HK$3.72
Previous CloseN/A
Volume341.00K
Average Volume (3M)2.03M
Market Cap
HK$401.84M
Enterprise Value-HK$38.70
Total Cash (Recent Filing)HK$69.24M
Total Debt (Recent Filing)HK$16.00K
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding528,737,060
10 Day Avg. Volume1,907,700
30 Day Avg. Volume2,030,864
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)0.99
Price to Sales (P/S)850.02
P/FCF Ratio-14.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$16.96M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low leverage and minimal debt reduce refinancing and solvency risk, providing the company lasting financial flexibility. This balance-sheet strength supports continued R&D or commercialization efforts and gives time to execute a recovery without immediate insolvency pressure.
Sizable Positive EquitySustained positive equity since 2021 is a structural buffer that supports liquidity and creditor confidence. It enables the firm to absorb ongoing losses, pursue strategic options, and access capital on better terms than a company with thin or negative equity over the medium term.
Improving Free Cash Flow TrendA less-negative free cash flow in the latest year signals early stabilization of cash burn and improving cash conversion dynamics. If sustained, this trend can meaningfully lower external funding needs and support a multimonth path toward operational break-even.
Bears Say
Severe Revenue CollapseA ~97% YoY revenue decline indicates a dramatic loss of commercial traction or product demand and is a structural threat to the business model. Such a collapse reduces scale economics, impairs customer relationships, and requires substantive product, go-to-market, or regulatory changes to restore revenue.
Persistent Unprofitability And Negative MarginsConsistent operating and net losses across multiple years show the company has not yet achieved a sustainable cost structure or revenue base. Prolonged unprofitability erodes retained earnings, limits reinvestment capacity, and increases the need for dilutive funding or debt to sustain operations.
Chronic Operating Cash BurnNegative operating and free cash flow in every reported year demonstrates persistent cash consumption and reliance on external capital. This structural cash burn constrains strategic investment, increases financing risk over months, and elevates the likelihood of future dilution or leverage if losses persist.
Broncus Holding Corp. News
2216 FAQ
What was Broncus Holding Corp.’s price range in the past 12 months?
Broncus Holding Corp. lowest stock price was HK$0.53 and its highest was HK$3.72 in the past 12 months.
What is Broncus Holding Corp.’s market cap?
Broncus Holding Corp.’s market cap is HK$401.84M.
When is Broncus Holding Corp.’s upcoming earnings report date?
Broncus Holding Corp.’s upcoming earnings report date is Aug 27, 2026 which is in 41 days.
How were Broncus Holding Corp.’s earnings last quarter?
Currently, no data Available
Is Broncus Holding Corp. overvalued?
According to Wall Street analysts Broncus Holding Corp.’s price is currently Overvalued.
Does Broncus Holding Corp. pay dividends?
Broncus Holding Corp. does not currently pay dividends.
What is Broncus Holding Corp.’s EPS estimate?
Broncus Holding Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Broncus Holding Corp. have?
Broncus Holding Corp. has 528,737,060 shares outstanding.
What happened to Broncus Holding Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Broncus Holding Corp.?
Currently, no hedge funds are holding shares in HK:2216
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Broncus Holding Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Broncus Holding Corp.
Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other international territories. The company's innovative product lineup includes advanced navigation systems such as LungPoint Virtual Bronchoscopic Navigation, a sophisticated computer-assisted image-based software solution. It also offers LungPoint Plus, a system providing real-time airway guidance crucial for lung biopsies and other medical interventions, and LungPro, a virtual bronchoscopic navigation product that enables three-dimensional real-time guided transbronchial needle aspiration alongside proprietary parenchymal navigation. Beyond navigation, Broncus provides a suite of therapeutic products. These feature InterVapor, a targeted bronchoscopic thermal vapor ablation system designed to treat diseased, hyper-inflated lung segments. Additionally, it offers an RF Generator paired with an RF Ablation Catheter, forming a radiofrequency ablation system specifically developed to target lung cancer. The H-Marker, a pulmonary surgical marker, is another key offering. The company further supplies a range of specialized procedural devices, including the BioStarNeedle, a single-use ultrasound-guided aspiration needle for retrieving tissue samples, and the FleXNeedle, a versatile multipurpose biopsy needle. Complementing these are various bronchoscopic accessories like the Archimedes Sheath, a sterile, single-use flexible tube that serves as a working channel during bronchoscopic procedures. The Archimedes Dilation Balloon, another sterile, single-use flexible tube with a distal balloon, is used to dilate target lung tissue within the bronchial tree after insertion through a bronchoscope or sheath. Finally, the Steerable Sheath provides a steerable adjustment handle and an additional working channel. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.
Technical Analysis
MicroPort Scientific
―
Vincent Medical Holdings Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
―
Rainmed Medical Limited
―






